Nanolute Technology

  • Conversion of Sirolimus drug into sub-micron sized particles
  • Nanocarriers created by encapsulation of sub-micron sized Sirolimus drug into highly biocompatible drug Carrier-phospholipid
  • Upon inflation of MagicTouch SCB at target site, nanocarriers with Sirolimus drug inside gets transferred to the vessel wall following the principle of co-efficient diffusion
  • Upon body pH variation, nanocarriers mimics the body lipids and liberates Sirolimus
  • The sub-micron sized Sirolimus drug particles penetrate the deepest layer of the vessel over a period

Challenges Addressed by Nanolute Technology

Improves Lipophilicity of Sirolimus

  • Lipophilicity is the ability of a drug to dissolve in fats, oils, lipids.
  • Sirolimus possess poor lipophilicity and hence require phospholipid.
  • NANOLUTE technology delivers polymer-free nanocarriers containing sirolimus surrounded by encapsulation of a proprietary drug carrier, i.e., a phospholipid and improves lipophilicity.

Enhanced Bioavailibility of Sirolimus

  • Bioavailability is a measure of the amount of a drug that reaches the target site.
  • The bioavailability of sirolimus is poor due to higher wash-out rate in the blood stream.
  • The coating of nanocarriers provides very low in-transit drug loss and better drug diffusion, as well as drug retention throughout the artery, and penetration of sirolimus to the deep layers of the coronary artery results in enhanced bioavailability.

Advantages of Nanolute Technology

  • Facilitates better adhesion of Sirolimus on the balloon surface

  • Effective drug transfer to the deepest layer of the vessel

  • Circumferential coating

  • Better in-tissue bioavailability of Sirolimus

Sirolimus Distribution Study

DTF labelled Sirolimus was used to study the drug distribution following DCB treatment*

A: Adventitia; EEL: External Elastic Lamina; IEL: Internal Elastic Lamina; L:Lumen; M: Media *EuroIntervention. 2013 May 20;9(1): 148-56

Products Designed using NANOLUTE TECHNOLOGY